https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2014-06-04 09:00:502022-08-17 15:14:02Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2013-10-02 09:00:232022-08-17 15:13:56Autifony Therapeutics wins Best Emerging Biotech Award at OBN Awards Dinner
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2013-07-01 09:00:342022-08-17 15:13:51Autifony Therapeutics Announces £2.75m Collaboration with Universities of Manchester and Newcastle to Progress a First-in-Class Drug for Schizophrenia
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2013-06-04 09:00:322022-08-17 15:13:45Autifony Therapeutics Initiates Phase I Study for Lead Product, AUT00063, for the Treatment of Hearing Loss and Tinnitus and Tops Up Series A Financing with Further 5.5 million Investment
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2012-11-14 09:00:252022-08-17 15:13:39‘The Abandoned Illness’ a report by the Schizophrenia Commission